Nanobiotix SA

Voting Rights and Shares Capital of the Company

08 Aug 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 Jul 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 Jun 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jun 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 Jun 2024 10:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 May 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 May 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 May 2024 02:00:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

21 May 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

16 May 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

15 May 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14 May 2024 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24 Apr 2024 16:40:39 By Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 Apr 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at Upcoming Investor Conferences in March

06 Mar 2024 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Feb 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

31 Jan 2024 16:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 Jan 2024 16:15:00 By Nasdaq GlobeNewswire